Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

1.820 -0.060 (-3.19%)

Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Volume	2,273,033
Open	1.860
Bid (Size)	1.810 (10,700)
Ask (Size)	1.820 (1,000)
Prev. Close	1.880
Today's Range	1.810 - 1.870
52wk Range	1.100 - 2.680
Shares Outstanding	144,474,452
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today ↗

September 28, 2026

An analyst at a prominent research firm initiated coverage of the

Via The Motley Fool

Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data ↗

September 20, 2026

Lexicon Pharmaceuticals (NASDAQ:LXRX) said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter...

Via MarketBeat

Performance

YTD	+59.6%	+59.6%
1 Month	-16.9%	-16.9%
3 Month	-21.6%	-21.6%
6 Month	+14.5%	+14.5%
1 Year	+29.1%	+29.1%

More News

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

September 01, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

August 31, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals (NASDAQ:LXRX) Falls as Q2 Revenue Misses Estimates ↗

August 06, 2026

Via Chartmill

Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rally ↗

July 08, 2026

Via Chartmill

Lexicon Pharmaceuticals (NASDAQ:LXRX) Q1 2026 Results Show Revenue Beat and Narrowed Loss ↗

May 07, 2026

Via Chartmill

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

August 24, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon (LXRX) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Via The Motley Fool

Lexicon Pharmaceuticals Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

August 06, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

July 30, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

July 27, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? ↗

June 11, 2026

Via The Motley Fool

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

June 03, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon (LXRX) Q1 2026 Earnings Transcript ↗

June 01, 2026

Via The Motley Fool

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 28, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

May 12, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Q1 Earnings Call Highlights ↗

May 08, 2026

Via MarketBeat

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

May 07, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

May 04, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

April 30, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

April 17, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

March 24, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

March 23, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Lexicon Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Lexicon Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Lexicon Pharmaceuticals, Inc. - Common Stock trade on?

Lexicon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock is LXRX on the Nasdaq Stock Market

What is the current price of Lexicon Pharmaceuticals, Inc. - Common Stock?

The current price of Lexicon Pharmaceuticals, Inc. - Common Stock is 1.820

When was Lexicon Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Lexicon Pharmaceuticals, Inc. - Common Stock was at 10/01/26 04:00 PM ET

What is the market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock is 262.94M

How many shares of Lexicon Pharmaceuticals, Inc. - Common Stock are outstanding?

Lexicon Pharmaceuticals, Inc. - Common Stock has 263M shares outstanding.